The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...
Strengthened the cash balance to provide runway into 2027, allowing Allarity to accelerate stenoparib's clinical development, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback